The American Society of Clinical Oncology (ASCO) has announced that the following guideline, “Systemic Treatment of Thyroid Cancer” is now open for public comment. This latest guideline incorporates new evidence to ensure the most current recommendations are provided.
As part of ASCO’s development process, they invite reviews and feedback for a 2-to-3-week period. Interested parties are encouraged to submit their comments here by December 2, 2024. Your input is invaluable in shaping the future of thyroid cancer management.
Copyright © 2024 Guideline Central, All Rights Reserved.